Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: TechSci Research | PRODUCT CODE: 1303143

Cover Image

PUBLISHER: TechSci Research | PRODUCT CODE: 1303143

Regenerative Wound Care Market-Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Type, By Wound Type, By End User, By Region and Competition

PUBLISHED:
PAGES: 118 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 4900
PDF and Excel (Multi-User License)
USD 5900
PDF and Excel (Custom Research License)
USD 8900

Add to Cart

We offer 8 hour analyst time for an additional research. Please contact us for the details.

Global Regenerative Wound Care Market is driven by the growing incidence of wounds caused due to burns, injuries, soars & ulcers, among others. Additionally, a growing geriatric population that is susceptible to various kinds of injuries and falls is expected to increase the demand for the regenerative wound care market. In the elderly population, due to various other associated conditions, the wound healing process is slow, leading to the demand for products that can bring about faster wound healing, thereby supporting market growth. According to the United Nations Department of Economic and Social Affairs, Population Division, the number of persons aged 65 years or above is expected to reach 1548.9 million by 2050.

The growing number of surgical procedures performed, along with increasing incidences of chronic burns, is further expected to increase the demand for the regenerative wound care market. Furthermore, the growing prevalence of diabetes is expected to fuel market growth in the coming years. Moreover, increasing research & development and new product approvals & launches are further expected to create lucrative opportunities for market growth. According to clinicaltrials.gov, as of 12th December, there are around 57 clinical trials registered across the globe related to regenerative wound care, which is in different phases of development worldwide. This, in turn, has led to the development and launch of new products. Organogenesis, Inc. was the first company to receive FDA approvals for a living, human cell-based product, Apligraf, and Dermagraft.

Apligraf is bioengineered with living cells that are bioactive to transform wounds from chronic to acute. Apligraf has illustrated clinical evidence in the treatment of Healing Venous Leg Ulcers and Diabetic Foot Ulcers. Apligraf resembles and functions like healthy human skin. Similarly, Dermagraft is a sterile, cryopreserved, human fibroblast-derived dermal substitute generated by the culture of neonatal dermal fibroblasts onto a bioabsorbable polyglactin mesh scaffold for the treatment of Diabetic Foot Ulcer in the United States.

Increasing cases of diabetes

The growing prevalence of diabetes is expected to increase the demand for regenerative wound care. Diabetes has become a pandemic in several developing nations, including China and India. Diabetes can increase the overall incidence and complexity of wounds, especially infections, chronic wounds, and ulcerations. This requires treatment and incurs exorbitant medical expenses. The World Health Organization (WHO) reports that non-communicable diseases caused 74% of deaths in 2019; diabetes killed 1.6 million people, making it the ninth largest cause of death worldwide. Globally and in emerging nations like India, the burden of diabetes is large and rising, primarily due to rising rates of overweight/obesity and unhealthy lifestyles. Numerous factors, such as abnormally high blood sugar, might damage blood vessels and nerves. This reduces blood flow to the hands, feet, and legs, which makes it more difficult for cuts and sores to heal. The Centers for Disease Control and Prevention (CDC) estimates that about 37.3 million people in the United States, or 11.3% of the population, have diabetes. Diabetes can also cause diabetic neuropathy, which can affect wound healing.

Increase in Incidences of Burns, Accidents, Injuries

The growing incidences of wounds caused due to surgeries, accidents, and injuries, among others, have significantly increased the demand for regenerative wound care. The tenth biggest cause of death globally is road traffic accidents, which are also the most common due to several factors such as speeding; driving under the influence of alcohol and other psychoactive substances; no-use of motorcycle helmets, seatbelts, and child restraints; distracted driving; unsafe vehicle; inadequate post-crash care and inadequate law enforcement of traffic laws. The WHO estimates that every year road traffic accidents claim the lives of over 1.3 million people. Between 20 and 50 million additional people have non-fatal injuries, with many of them becoming disabled as a result.

Market Segmentation

Global Regenerative Wound Care Market can be segmented by type, by wound type, by end-user, and by region. Based on type, the market can be categorized into autologous stem cells, biological skin substitutes, tissue/multiple tissue platforms, fetal skin, regenerative wound care devices, and others. Based on wound type, the market can be fragmented into ulcers, surgical & traumatic wounds, and burns. Ulcers can further be divided into diabetic foot ulcers, pressure ulcers, and others. Based on end-user, the market can be grouped into hospitals, ambulatory surgical centers, burn care centers & wound clinics, and others. Regionally, the market can be segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa.

Market Players

DeCell Technologies Inc., Avita Medical, Inc., Organogenesis, Inc., Histogen, Inc., RenovoDerm (Nanofiber Solutions, LLC), StemsysBio, Koninklijke DSM N.V., MiMedx Group, Inc., among others, are some of the leading players operating in the global regenerative wound care market.

Recent Developments

Global Regenerative Wound Care Market is witnessing a lot of new developments in the form of mergers & acquisitions, new product launches, launching new clinical trials, increasing research & development activities, and making investments, among others, in order to stay competitive and an edge over the other players operating in the market.

  • In June 2021, MiMedx Group, Inc. received approval for the commercialization of its product Epifix in Japan from the Japanese Ministry of Health, Labour, and Welfare.
  • In May 2019, Organogenesis Inc. entered into an agreement with Vizient, Inc. This, in turn, helped Organogenesis increase its wound care product offerings and improve its market positioning.

Report Scope

In this report, Global Regenerative Wound Care Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Regenerative Wound Care Market, By type:

  • Autologous Stem Cells
  • Biological Skin Substitutes
  • Tissue/Multiple Tissue Platform
  • Fetal Skin
  • Regenerative Wound Care Devices
  • Others

Regenerative Wound Care Market, By Wound Type:

  • Ulcers
  • Diabetic Foot Ulcers
  • Pressure Ulcers
  • Others
  • Surgical & Traumatic Wounds
  • Burns

Regenerative Wound Care Market, By End User:

  • Hospitals
  • Ambulatory Surgical Centers
  • Burn Care Centers & Wound Clinics
  • Others

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Regenerative Wound Care Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).
Product Code: 14405

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

  • 5.1. Ongoing Clinical Trials
  • 5.2. Completed Clinical Trials
  • 5.3. Terminated Clinical Trials
  • 5.4. Breakdown of Pipeline, By Development Phase
  • 5.5. Breakdown of Pipeline, By Status
  • 5.6. Breakdown of Pipeline, By Study Application
  • 5.7. Breakdown of Pipeline, By Region
  • 5.8. Clinical Trials Heat Map

6. Global Regenerative Wound Care Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 6.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
      • 6.2.2.1. By Ulcers (Diabetic Foot Ulcers, Pressure Ulcers, Others)
    • 6.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 6.2.4. By Region
    • 6.2.5. By Company (2022)
  • 6.3. Market Map

7. North America Regenerative Wound Care Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 7.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
      • 7.2.2.1. By Ulcers (Diabetic Foot Ulcers, Pressure Ulcers, Others)
    • 7.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Regenerative Wound Care Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Wound Type
        • 7.3.1.2.3. By End User
    • 7.3.2. Canada Regenerative Wound Care Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Wound Type
        • 7.3.2.2.3. By End User
    • 7.3.3. Mexico Regenerative Wound Care Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Wound Type
        • 7.3.3.2.3. By End User

8. Europe Regenerative Wound Care Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. B By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 8.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
      • 8.2.2.1. By Ulcers (Diabetic Foot Ulcers, Pressure Ulcers, Others)
    • 8.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 8.2.4. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Regenerative Wound Care Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Wound Type
        • 8.3.1.2.3. By End User
    • 8.3.2. Germany Regenerative Wound Care Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Wound Type
        • 8.3.2.2.3. By End User
    • 8.3.3. United Kingdom Regenerative Wound Care Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Wound Type
        • 8.3.3.2.3. By End User
    • 8.3.4. Italy Regenerative Wound Care Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Wound Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Spain Regenerative Wound Care Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Wound Type
        • 8.3.5.2.3. By End User

9. Asia-Pacific Regenerative Wound Care Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 9.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
      • 9.2.2.1. By Ulcers (Diabetic Foot Ulcers, Pressure Ulcers, Others)
    • 9.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 9.2.4. By Country
  • 9.3. Asia-Pacific: Country Analysis
    • 9.3.1. China Regenerative Wound Care Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Wound Type
        • 9.3.1.2.3. By End User
    • 9.3.2. India Regenerative Wound Care Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Wound Type
        • 9.3.2.2.3. By End User
    • 9.3.3. Japan Regenerative Wound Care Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Wound Type
        • 9.3.3.2.3. By End User
    • 9.3.4. South Korea Regenerative Wound Care Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Type
        • 9.3.4.2.2. By Wound Type
        • 9.3.4.2.3. By End User
    • 9.3.5. Australia Regenerative Wound Care Market Outlook
      • 9.3.5.1. Market Size & Forecast
        • 9.3.5.1.1. By Value
      • 9.3.5.2. Market Share & Forecast
        • 9.3.5.2.1. By Type
        • 9.3.5.2.2. By Wound Type
        • 9.3.5.2.3. By End User

10. South America Regenerative Wound Care Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 10.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
      • 10.2.2.1. By Ulcers (Diabetic Foot Ulcers, Pressure Ulcers, Others)
    • 10.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Regenerative Wound Care Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Wound Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Argentina Regenerative Wound Care Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Wound Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Colombia Regenerative Wound Care Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Wound Type
        • 10.3.3.2.3. By End User

11. Middle East and Africa Regenerative Wound Care Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Type (Autologous Stem Cells, Biological Skin Substitutes, Tissue/Multiple Tissue Platform, Fetal Skin, Regenerative Wound Care Devices, Others)
    • 11.2.2. By Wound Type (Ulcers, Surgical & Traumatic Wounds, Burns)
      • 11.2.2.1. By Ulcers (Diabetic Foot Ulcers, Pressure Ulcers, Others)
    • 11.2.3. By End User (Hospitals, Ambulatory Surgical Centers, Burn Care Centers & Wound Clinics, Others)
    • 11.2.4. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Regenerative Wound Care Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Type
        • 11.3.1.2.2. By Wound Type
        • 11.3.1.2.3. By End User
    • 11.3.2. Saudi Arabia Regenerative Wound Care Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Type
        • 11.3.2.2.2. By Wound Type
        • 11.3.2.2.3. By End User
    • 11.3.3. UAE Regenerative Wound Care Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Type
        • 11.3.3.2.2. By Wound Type
        • 11.3.3.2.3. By End User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

  • 13.1. Recent Developments
  • 13.2. Mergers & Acquisitions
  • 13.3. Product Launches

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Company Snapshot
  • 14.3. Products & Services
  • 14.4. Financials (As Reported)
  • 14.5. Recent Developments
  • 14.6. SWOT Analysis
    • 14.6.1. DeCell Technologies Inc.
    • 14.6.2. Avita Medical, Inc.
    • 14.6.3. Organogenesis, Inc.
    • 14.6.4. Histogen, Inc.
    • 14.6.5. RenovoDerm (Nanofiber Solutions, LLC)
    • 14.6.6. StemsysBio
    • 14.6.7. Koninklijke DSM N.V.
    • 14.6.8. MiMedx Group, Inc.

15. Strategic Recommendations

Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!